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γ-secretases: from cell biology to therapeutic strategies
Bruno A Bergmans, Bart De Strooper
Presenilins form the catalytic part of the γ-secretases, protein complexes that are responsible for the intramembranous 
cleavage of transmembrane proteins. The presenilins are involved in several biological functions, but are best known for 
their role in the generation of the β-amyloid (Aβ) peptide in Alzheimer’s disease and are therefore thought to be 
important drug targets for this disorder. Mutations in the presenilin genes cause early-onset familial Alzheimer’s disease, 
but mutation carriers have substantial phenotypic heterogeneity. Recent evidence implicating presenilin mutations 
in non-Alzheimer’s dementias, including frontotemporal dementia and Lewy body dementia, warrants further investi -
gation. An increased understanding of the diversity of the molecular cell biology of the γ-secretase complex and the 
eﬀ ects of clinical mutations in the presenilin genes might help pave the way for improved development of drugs that are 
designed to target γ-secretase enzymatic activity in Alzheimer’s disease and potentially in other neurological diseases. 
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Introduction
Presenilins ﬁ rst caught the attention of the scientiﬁ c world 
with the identiﬁ cation of pathogenic mutations in the 
encoding gene PSEN1 in several families with early-onset 
Alzheimer’s disease.1 Soon after, mutations in a similar 
gene, PSEN2 (presenilin 2), were found.2–4 More than 
170 mutations have since been identiﬁ ed in PSEN1, 
whereas mutations in PSEN2 are much rarer.5 Presenilin 
mutations are responsible for an important fraction of 
autosomal inherited Alzheimer’s disease, although 
estimates vary from 9%6 to 62%.7–9 On the basis of the latter 
percentage, presenilin mutations combined with mutations 
in the APP (amyloid precursor protein) gene could account 
for up to 82% of mutations8,9 that cause early-onset genetic 
Alzheimer’s disease. Since 1995, no new genes have been 
identiﬁ ed and it therefore seems reasonable to suggest that 
all major monogenic loci have been found and that other 
families with inherited early-onset Alzheimer’s disease 
most probably have a more complex, oligogenetic 
aetiology.10 However, as only about 2% of patients with 
Alzheimer’s disease have early onset,11 the total contribution 
of APP and the presenilin genes to the risk of Alzheimer’s 
disease in the general population remains low.12 Despite 
years of association studies and meta-analyses, until very 
recently the only ﬁ rmly established risk factor for sporadic 
Alzheimer’s disease was variants in APOE (the gene that 
encodes apolipoprotein E), with two copies of the APOE ε4 
allele leading to an eightfold increase in the risk for 
Alzheimer’s disease.13–15 However, three more genes that 
confer risk for sporadic Alzheimer’s disease have recently 
been uncovered in genome-wide association studies—CR1 
(complement component receptor 1), CLU (clusterin), and 
PICALM (phosphatidylinositol binding clathrin assembly 
protein)—which all might directly or indirectly aﬀ ect the 
β-amyloid (Aβ) pathway.16,17
The importance of the identiﬁ cation of the presenilin 
mutations for research into Alzheimer’s disease should, 
however, not be underestimated. Their disovery has 
enhanced understanding of a crucial enzymatic process in 
the generation of the Aβ peptide,18 which is thought to be a 
key factor in the pathogenesis of the disease.19 Moreover, 
together with the other proteases involved in APP 
processing, the presenilins have become one of the few 
advanced drug targets in Alzheimer’s disease. In this 
Review, we update our current knowledge about presenilins 
in Alzheimer’s disease and critically evaluate evidence that 
implicates presenilins in other neuro degenerative diseases. 
We also discuss the potential of presenilins and γ-secretases 
as drug targets for the treatment of Alzheimer’s disease. 
Basic cell biology of presenilin
The two presenilins are highly homologous (about 80%) 
nine-transmembrane domain proteins (ﬁ gure 1). 
Presenilins provide the catalytic core to the multimeric 
γ-secretase enzymatic comp lex es,22,23 which also contain 
nicastrin, presenilin enhancer 2 (Pen-2), and anterior 
pharynx defective 1 (Aph1).20 γ-secretases cleave various 
type I transmembrane proteins, including the adhesion 
molecules N-cadherin and E-cadherin,24,25 the neuro-
trophin receptor p75,26 the regulatory β2 subunit of 
voltage-gated sodium channels,27 the axon guidance 
molecule DCC,28 and neuregulin29 (for a review see 
elsewhere30). Neuregulin has an important role in myelin 
formation,31 and single nucleotide polymorphisms in the 
gene have been associated with an increased risk of 
neurodevelopmental disorders.32–34 A deﬁ ciency in a 
γ-secretase subtype (see below) in mice causes disturbed 
neuregulin processing in the brain, possibly causing 
prepulse inhibition, increased dopaminergic tonus, and 
behavioural symptoms relevant to neurodevelopmental 
disorders such as schizophrenia.29 The two substrates with 
the most far-reaching pathophysiological consequences 
are, however, APP and the Notch receptor, which we 
discuss in more detail below.
APP processing 
Aβ peptides are generated through the processing of APP 
by β-secretase and γ-secretase in a stepwise fashion 
(ﬁ gure 1). After the β-secretase enzyme cleaves the APP 
extracellular domain, γ-secretase cleaves the remaining 
segment to release the Aβ peptide.22,23,35 These Aβ peptides 
can aggregate into small neurotoxic oligomeric structures 
and eventually form the typical senile plaques seen in 
Alzheimer’s disease. γ-secretase cleaves APP at diﬀ erent 
positions, possibly in a consecutive way, resulting in the 
release of several Aβ peptides that contain between 37 and 
For more on PSEN2 see http://
www.ncbi.nlm.nih.gov/entrez/
dispomim.cgi?id=600759
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49 amino-acid residues (Aβ37 to Aβ49). Aβ40 is the most 
abundant product cleaved and is found in the CSF and 
the plasma. Aβ42 is less common, occurring in about a 
tenth of the amounts of Aβ40, but is considered to be 
pathogenic. This peptide aggregates faster than Aβ40 and 
is apparently also more toxic in cell culture assays.36–38 The 
presenilin mutations generally increase the relative 
amounts of Aβ42 to Aβ40, and this ratio is widely regarded 
as an important indicator of pathogenic mutations.39 The 
extent to which other long Aβ peptides (Aβ43 to Aβ49) are 
secreted or degraded intracellularly and whether they also 
have pathological importance remain unclear. Shorter 
peptides (Aβ38 and shorter) might be less problematic 
because they are more soluble, but this remains unproven. 
Novel drugs that are under investigation target γ-secretases 
with the aim of modulating, rather than inhibiting, their 
activity, so that more of the shorter Aβ peptides are 
generated (see below).
Notch processing
After binding of its ligands, such as delta and serrate, 
Notch is ﬁ rst cleaved by a metalloproteinase, ADAM10 (a 
disintegrin and metallopeptidase;40–42 but see elsewhere 
for a contrasting view43), in its extracellular domain, which 
triggers cleavage by γ-secretase in the transmembrane 
domain.18,44 The Notch intracellular domain is then 
released and translocates to the nucleus to regulate the 
transcription of a set of target genes involved in 
development and diﬀ erentiation. This makes Notch 
important for the diﬀ erentiation of many cell types, not 
only during embryonic development, but also in adult 
life.45–47 Interference with the Notch pathway therefore 
leads to many disturbances in embryogenesis, including 
disrupted somito genesis and blood vessel formation.45,47 
The Notch pathway also regulates several oncogenes and 
oncogenic signalling pathways such as those that involve 
Myc and Akt.48 These pathways are of relevance for cancer, 
which, as we brieﬂ y discuss, is why γ-secretase inhibitors 
are also considered for the treatment of some human 
cancers. Both genetic and pharmacological experiments 
in mouse, ﬁ sh, and ﬂ y models indicate, however, that a 
major concern for γ-secretase inhibitors is the side-eﬀ ects 
that result from interference with Notch cleavage and 
signalling.49,50 In the context of Alzheimer’s disease, the 
inhibition of Notch signalling by γ-secretase inhibitors 
has to be considered as an intrinsic, mechanism-based 
cause of serious side-eﬀ ects, including gastrointestinal 
bleedings, immune disturbances, and hair loss.18,51–54
Presenilins and intracellular calcium
Recent studies have indicated that the function of 
presenilins extends beyond their role in γ-secretase 
cleavage. These proteins constitute calcium leak channels 
in the endoplasmic reticulum when not incorporated into 
the γ-secretase complexes.55 Mutations seen in Alzheimer’s 
disease disturb this leak function and possibly also aﬀ ect 
the regulation of ryanodine receptors and inositol 
1,4,5-trisphosphate receptors,56–60 leading to increased 
accumulation of calcium ions (Ca²+) in the endoplasmic 
reticulum.61 A conditional knockout model of the 
presenilins in the hippocampus showed disturbances in 
neurons in the CA3 region, but this ﬁ nding was explained 
by an eﬀ ect on ryanodine receptor-mediated release of Ca²+ 
from the endoplasmic reticulum, which modulated 
glutamatergic neurotransmitter release and disturbed 
long-term potentiation via a presynaptic mechanism.62 A 
conditional knockout mouse model of both presenilins in 
the forebrain showed marked neurodegeneration with 
increasing age.63 It is unclear whether the neuro-
degeneration in this model is linked to the early presynaptic 
deﬁ cits and whether impaired γ-secretase (proteolytic) 
function or disturbed Ca²+ homoeostasis underlie this 
pathology. Therefore, the extent to which these calcium 
eﬀ ects are relevant to the pathogenesis of Alzheimer’s 
disease in human beings remains to be determined.
Loss-of-function or gain-of-function of presenilin in 
Alzheimer’s disease 
The question of whether the presenilin clinical mutations 
confer gain-of-function or loss-of-function eﬀ ects has 
Figure 1: Presenilins, the γ-secretase complex, and APP processing
After release of sAPP by β-secretase, the remaining APP segment is further cleaved by γ-secretase. First, ε-cleavage 
by γ-secretase releases the AICD. Second, γ-secretase cleavage releases the Aβ peptide, of which there can be 
longer and shorter forms (eg, Aβ40 and Aβ42), depending on the exact cleavage site by γ-secretase. The γ-secretase 
enzyme consists of four components: PSEN, Aph1, Nct, and Pen-2.20 The magniﬁ ed area shows the nine TM 
domains of PSEN.21 The two red circles indicate the catalytic aspartates. Aβ=β-amyloid. AICD=APP intracellular 
domain. Aph1=anterior pharynx defective. APP=amyloid precursor protein. Nct=nicastrin. Pen-2=presenilin 2 
enhancer. PSEN=presenilin. sAPP=soluble APP. TM=transmembrane.
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been much debated in recent years.64,65 It is becoming 
increasingly clear that, from a genetic point of view, 
mutations act in a “dominant” fashion, whereas from a 
biochemical view, most have loss-of-function eﬀ ects, 
both in enzymatic assays66 or when measuring Ca²+ 
leakage channel activity.61 Many clinical mutations clearly 
have loss-of-function eﬀ ects on some substrates such as 
syndecan, N-cadherin,66 and Notch.66–68 The eﬀ ects on 
APP processing are, however, more varied. Most 
mutations tested lead to a decrease in total Aβ production 
(biochemical loss-of-function), whereas a few mutations 
give rise to an increase in Aβ42.66,69 The net result is that, 
even if the total amount of Aβ peptides decreases, there 
is an increase in the Aβ42:Aβ40 ratio, which might aﬀ ect 
the formation of toxic Aβ oligomers.
An important conclusion, therefore, is that the absolute 
amount of Aβ peptides generated seems to be less crucial 
than the particular type of Aβ peptide, at least in familial 
Alzheimer’s disease linked to presenilin mutations. The 
recent insight that amyloid plaques or single Aβ peptides 
are not extremely toxic,70 but that an ill-deﬁ ned oligomeric 
state of Aβ peptides aﬀ ects synapses and neurons, might 
provide an explanation for this apparent paradox.71,72 
Although not proven, the ratio of longer or more 
hydrophobic Aβ peptides (Aβ42, but also longer or 
truncated species) to Aβ40 and possibly other shorter 
species might determine a complex equilibrium between 
monomers, oligomers, and ﬁ brils. If true, the quality 
rather than the quantity of the Aβ peptides could drive 
oligomer conformation and disease. The situation is not 
straightforward, because increasing the amount of 
Aβ peptides without a change in ratio can also cause 
Alzheimer’s disease, as seen with the APP mutation in a 
Swedish family.73 The question is thus whether we need a 
quantitative or a qualitative decrease in Aβ to prevent or 
treat Alzheimer’s disease. Both approaches—blocking 
and modulating γ-secretase activity—are currently being 
considered, as discussed below. In this regard, the ﬁ nding 
that a global decrease in total Aβ (rather than a speciﬁ c 
reduction in Aβ42) diminishes amyloid plaque load and 
memory deﬁ cits in a mouse model74–76 suggests that a 
total Aβ decrease might still be a valuable therapeutic 
option. However, the available transgenic Alzheimer’s 
disease mouse models come with their own limitations: 
the pathology in these models is generally driven by high 
Aβ production, which is not necessarily the situation for 
all cases of human Alzheimer’s disease.
The heterogeneity of the clinical phenotype 
caused by presenilin mutations
Mutations in the presenilin genes cause autosomal 
dominant early-onset Alzheimer’s disease but in recent 
years the presenilins have also been implicated in other 
clinical disorders such as spastic paraparesis, 
frontotemporal dementia, and Lewy body dementia. 
Although the link to Alzheimer’s disease is undisputable, 
mutation carriers have a high phenotypic heterogeneity, 
most notably in the age at onset. This feature remains 
insuﬃ  ciently investigated and could provide clues to a 
better understanding of genetic and environmental 
modulators of the disease.
Age at onset 
The ﬁ rst symptoms associated with Alzheimer’s disease 
in patients with PSEN1 mutations are generally observed 
in the ﬁ fth decade of life, although can be seen in the 
third decade in some families.77 Alzheimer’s disease 
related to PSEN2 mutations has a later and more variable 
age of onset, between the ages of 45 and 88 years (on 
average in the sixth decade); patients with Alzheimer’s 
disease related to these mutations live longer and have a 
longer disease duration than do patients with PSEN1 
mutations.77,78 The reason why PSEN2 mutations manifest 
at an older age than do PSEN1 mutations is unclear, and 
further work on the diﬀ erential tissue distribution or the 
reported diﬀ erences79,80 in molecular properties of PSEN2 
or γ-secretase might yield an explanation.
In contrast to sporadic Alzheimer’s disease, no major 
modiﬁ ers of age at onset have been identiﬁ ed in patients 
with early-onset familial disease.81,82 The only modiﬁ er 
suggested in families with early-onset disease is the 
HLA-2 genotype, but the precise mechanism is 
unclear.83,84 
Spastic paraparesis 
After the original suggestion of an association between 
early-onset Alzheimer’s disease and spastic paraparesis85 
and the conﬁ rmation in a large Finnish family,86,87 more 
PSEN1 mutations have been linked to this variant form 
of Alzheimer’s disease in some individuals (these 
mutations are reviewed in the table). Autopsy reports of 
this variant of Alzheimer’s disease note corticospinal 
tract degeneration at the level of the medulla and the 
spinal cord.91,114 Hypometabolism on ﬂ uorodeoxyglucose-
PET in the motor cortex, a sign of malfunction, has also 
been reported.94 There is widespread presence of “cotton 
wool” plaques in the hippocampus and the primary and 
association cortices in these patients.114 These plaques do 
not have the congophilic staining typical of the “canonical” 
Alzheimer’s disease plaques, and they also have very few 
dystrophic neurites, but they retain immunoreactivity for 
the Aβ peptide (ﬁ gure 2). It is unclear whether these 
cotton wool plaques have a particular eﬀ ect on the 
neurons. The canonical-cored plaques with tau-positive 
dystrophic neurites also occur in these patients. 
Spastic paraparesis occurs in only a few of the family 
members studied, while other family members present 
with a typical picture of Alzheimer’s disease dementia. 
This indicates the occurrence of gene modiﬁ ers that 
increase the sensitivity of these particular patients to 
damage to neurological systems outside the cognitive 
system. In one study, mutations in known spastic 
paraplegia genes (spastin [SPAST], paraplegin [SPG], and 
atlastin [ATL], which cause more than 50% of cases of 
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hereditary spastic paraplegia) and other Alzheimer’s 
disease genes were excluded as gene modiﬁ ers of the 
disease phenotype, indicating that further work is needed 
to explain this particular variant of Alzheimer’s 
disease.105 
Apart from their eﬀ ect on Aβ generation, there are 
several hypotheses to explain why presenilin mutations 
could interfere with neuronal function. Their 
involvement in Ca²+ homoeostasis at several levels and 
their eﬀ ects on synaptic transmission might have a role. 
Data from a recent study suggest that presenilin could 
be involved in motor neuron fast axonal traﬃ  cking. In 
mice that expressed a mutant form of presenilin with 
exon 9 deleted, functional motor deﬁ cits were 
observed.115,116 However, the precise molecular mechanism 
by which presenilin mutations might sometimes cause 
additional motor neuron degeneration requires further 
investigation.
Other neurodegenerative diseases
Several case reports have suggested a link between 
presenilin mutations and Lewy body dementia, 
Domain Exon Population Unusual clinical features Unusual pathology Functional implications/
eﬀ ect on Aβ
Dell83/Met8488.89 TM1 4 Scotland None CWP, AA ↑ Aβ42 in cell lines
Leu85Pro90 TM1 4 Japan In combination with visual variant 
of Alzheimer’s disease
No autopsy data available ↑ Aβ42 in cell lines
Asn135Ser91 TM2 5 Greece Seizures Corticospinal tract degeneration Not tested
Met139Val92 TM2 5 USA, UK, 
Germany
Seizures, myoclonus, 
cerebellar ataxia
Pathology in basal ganglia and 
cerebellum
Not tested
Tyr154Asn93 TM2 5 Japan None No autopsy data available Not tested
insPhe157I/15894 Loop 2 5 USA Apraxia, dystonia CWP Not tested
Leu166Pro95 TM3 6 Germany Seizures, cerebellar ataxia, onset 
in adolescence
CWP including in the cerebellum ↑ Aβ42 in cell lines
Phe237Ile96 TM5 7 Japan Seizures, myoclonus, dystonia No autopsy data available Not tested
Tyr256Ser97 TM6 7 Australia Extrapyramidal signs, 
cerebellar ataxia
CWP ↑ Aβ42 in brain
Val261Leu98 TM6 8 Spain None No autopsy data available Not tested
Val261Phe99 TM6 8 USA None No autopsy data available Not tested
Pro264Leu100 Loop 6 8 France Seizures and myoclonus, 
visuospatial impairment 
No autopsy data available Not tested
Gly266Ser101 Loop 6 8 Japan Apraxia No autopsy data available Not tested
Arg278Lys102 Loop 6 8 Italy 1 of 3 patients in this kindred had 
spastic paraparesis without dementia
No autopsy data available ↑ Aβ42:Aβ40 ratio in cell lines
Arg278Ser103 Loop 6 8 UK Visuospatial impairment No autopsy data available Not tested
Arg278Thr86 Loop 6 8 Australia None No autopsy data available Not tested
Glu280Gly104 Loop 6 8 Ireland Deep white matter abnormalities 
on MRI
CWP, AA Not tested
Glu280Gln105 Loop 6 8 Canada None CWP, Lewy bodies, corticospinal 
tract degeneration
Not tested
Pro284Leu106 Loop 6 8 Japan Extrapyramidal signs CWP Not tested
Pro284Ser107 Loop 6 8 Italy Frontal and temporal white matter 
abnormalities on MRI
No autopsy data available Not tested
G to T splice acceptor 
site substitution86
Loop 6 9 Japan None No autopsy data available Functional del290-319 
G to A splice acceptor 
site substitution108
Loop 6 9 Australia None CWP, AA Functional del290-319 
DelExon987,88 Loop 6 9 Finland None CWP ↑ Aβ42 in cell lines and 
in brain
DelExon9109 Loop 6 9 Australia None CWP Not tested
Leu381Val110 TM7 11 Bulgaria Extrapyramidal signs No autopsy data available Not tested
Asn405Ser111 Loop 7 11 Japan None Some AA Not tested
Pro436Gln88 TM9 12 UK None CWP ↑ Aβ42 in cell lines
DelThr440112 TM9 12 Japan Extrapyramidal signs CWP, AA, Lewy bodies, 
corticospinal tract degeneration
Not tested
For a comprehensive list of studies of clinical heterogeneity associated with PSEN1 mutations in Alzheimer’s disease, see elsewhere.113 AA=amyloid angiopathy. 
Aβ=β-amyloid. CWP=cotton-wool plaques. PSEN1=presenilin 1 gene. TM=transmembrane domain.
Table: Overview of PSEN1 mutations associated with early-onset Alzheimer’s disease and spastic paraparesis 
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frontotemporal dementia, and cerebral amyloid 
angiopathy, indicating that presenilin mutations could be 
implicated in an even broader clinical range of diseases 
than originally thought. 
Three independent reports have been published linking 
particular mutations in PSEN1 to frontotemporal 
dementia: Leu113Pro, insArg352, and Gly184Val.117–119 
Patients with the Leu113Pro mutations118 had typical 
Alzheimer’s disease neuropathology (with plaques and 
tangles), but had prominent involvement of the frontal 
cortex. Therefore, these patients seemed to have a frontal 
variant of Alzheimer’s disease, rather than frontotemporal 
dementia (Campion D, personal communication). In the 
insArg352 case report,117 the mutation aﬀ ected APP 
processing by decreasing Aβ production. On neuro-
pathological examination of the proband, however, fronto-
temporal lobar degeneration with ubiquitin-positive 
inclusions was found, suggestive of a progranulin 
mutation. In a follow-up report, this patient was also 
found to have a progranulin mutation, which is probably 
the real cause of the observed pathology.120 The relevance 
of the presenilin mutation or polymorphism remains 
unclear. Finally, the Gly184Val case had a Pick-type 
tauopathy without extracellular Aβ plaques.119 In the 
meantime, progranulin and MAPT (microtubule-
associated protein tau; Tau) mutations in this family have 
been excluded,121 leaving the possibility that the Gly184Val 
mutation could be pathological; however, in the absence 
of further published pathological investigation, it remains 
unclear whether and to what extent the other four 
reported carriers in the family had a similar Pick’s disease 
phenotype.119 Such work is essential to begin to establish 
a causal relationship. 
Lewy bodies are also frequently observed in patients 
with both familial and sporadic Alzheimer’s disease, but 
these are fewer and less widespread than seen in patients 
with typical Lewy body disease.122 One case report of a 
patient with a PSEN2 mutation presenting with 
widespread Lewy bodies and a full clinical picture of 
Lewy body dementia has been published.123 However, 
only one of the ﬁ ve patients in this family had this clinical 
presentation, whereas other family members presented 
with more typical symptoms of Alzheimer’s disease.
In conclusion, the evidence linking presenilin 
mutations to other neurodegenerative diseases apart 
from Alzheimer’s disease seems to be weak. The range 
of clinical symptoms caused by the diﬀ erent presenilin 
mutations is quite heterogeneous, and further work is 
needed to understand this. Given the complex cell 
biology and the various functions in which the 
γ-secretase complex is involved, the diﬀ erent mutations 
in presenilin, apart from their eﬀ ect on Aβ processing,66 
might have a heterogeneous eﬀ ect on other aspects of 
its biology. Such eﬀ ects might also partly contribute to 
the clinical variability. Moreover, the two presenilin 
proteins can combine into diﬀ erent γ-secretase 
complexes. Whether these diﬀ erent complexes are 
involved in diﬀ erent aspects of the pathology remains 
to be fully investigated. In the next section, we discuss 
how this heterogeneity might aﬀ ect therapeutic options 
in Alzheimer’s disease and beyond.
γ-secretases: therapeutic opportunities and 
challenges 
As γ-secretase is the ﬁ nal protease involved in the 
production of Aβ peptides, it is, at least with regard to the 
amyloid hypothesis of Alzheimer’s disease pathogenesis, 
a very attractive drug target. Given its central role in 
Notch cleavage, the protease is also increasingly 
considered as a drug target for cancer. Therefore, 
compounds that eﬃ  ciently target γ-secretase could have 
a wide range of therapeutic uses. Here, we brieﬂ y discuss 
the therapeutic potential and challenges of γ-secretase 
inhibitors and γ-secretase modulators. Insights into the 
A
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Figure 2: Plaque pathology in Alzheimer’s disease
Cotton-wool plaques are typically seen in the brains of patients with Alzheimer’s disease and spastic paraparesis. 
(A) Entorhinal cortex showing cotton wool plaques (modiﬁ ed Bielschowsky silver stain, 200×). (B) Cortex 
showing Aβ staining of a diﬀ use plaque (Aβ stain, 400×). (C) Cortex showing a classic plaque (Aβ stain, 400×). 
Aβ=β-amyloid. Reproduced from Brooks and colleagues,108  with permission from Oxford University Press.
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heterogeneity of the γ-secretase complex and the 
regulatory role of G-protein-coupled receptors might also 
provide opportunities for the development of novel 
therapies.
γ-secretase inhibitors 
Several γ-secretase inhibitors have been developed and 
tested preclinically and clinically. The ﬁ rst results in animal 
models were promising, and brain Aβ concentrations 
were reduced in a mouse model of Alzheimer’s disease.124 
The ﬁ rst reports raised hope for cancer as well; for example, 
γ-secretase inhibitors increased survival in mouse models 
of leukaemia.125 These inhibitors also reduced osteo-
sarcomas in vivo in mice126 and had a synergistic eﬀ ect 
with other chemotherapy approaches in human colon 
adenocarcinoma cell lines.127 γ-secretase inhibitors also 
seemed to have beneﬁ cial eﬀ ects in a model of focal 
ischaemic stroke,128 probably via inhibition of Notch 
signalling. In an experimental model of multiple sclerosis, 
γ-secretase inhibitors have enhanced remyelination and 
reduced axonal damage.129 In these models, the drugs 
could be given over a short time period, which reduces the 
likelihood of severe adverse events, as discussed below. 
The results of the ﬁ rst clinical trials have raised 
important questions about the therapeutic potential and 
possible complications of γ-secretase inhibitors. For 
example, trials of γ-secretase inhibitors in patients with 
T-cell acute lymphoblastic leukaemia resulted in 
serious gastrointestinal side-eﬀ ects,52,54,130,131 and their anti -
leukaemic eﬀ ects seemed very limited.52,132–134 LY450139 
(semagacestat) is currently being studied for Alzheimer’s 
disease in a phase 3 clinical trial.135 In the phase 2 trial, 
this γ-secretase inhibitor decreased plasma Aβ40 concen-
trations by more than 50%.136 However, this response was 
biphasic with an increase in Aβ concentrations after the 
initial reduction. Reductions in Aβ in the CSF were not 
signiﬁ cant. 
So far, owing to their inhibition of Notch cleavage as 
well as their inhibition of APP cleavage, all the tested 
γ-secretase inhibitors have led to serious gastrointestinal 
side-eﬀ ects in animals because of the transformation of 
proliferative intestinal crypt cells into postmitotic goblet 
cells.54,130,131 In mice, they also aﬀ ected the maturation of 
B lymphocytes and T lymphocytes, causing immuno-
suppression.53 By contrast, the side-eﬀ ects of semagacestat 
reported in a phase 2 trial136–138 were relatively mild, 
possibly because γ-secretase was not completely inhibited. 
Three patients had to stop the trial because of 
gastrointestinal side-eﬀ ects, but these adverse events did 
not seem to be caused by immediate Notch-related 
toxicity. At a high dosage, prolonged QT intervals were 
observed on electro cardiogram (ECG) scans. Other 
notable side-eﬀ ects included skin rashes and changes to 
hair colour: on withdrawal of the drug, these were 
reversible.136–138 As the drug has to be carefully dosed to 
avoid Notch-related toxicity, the changes in Aβ 
concentrations in the phase 3 trial might not be suﬃ  cient 
to provide information on the clinical correlates of 
chronically decreasing Aβ production in the brain. 
To avoid Notch-related toxicity, inhibitors such as 
begacestat have recently been developed that apparently 
have a limited eﬀ ect on Notch signalling pathways, while 
inhibiting APP cleavage.139,140 So far, BMS-708163 is the 
most advanced of these compounds in clinical trials.141,142
An alternative way to avoid the gastrointestinal toxicity 
of γ-secretase inhibitors came from work in cancer 
research. Glucocorticoids are normally part of the 
therapeutic armamentarium against T-cell acute lympho-
blastic leukaemia. However, some patients develop 
glucocorticoid resistance owing to Notch mutations.143 In 
a recent study, a twofold beneﬁ t of combina tion therapy 
with a γ-secretase inhibitor and gluco corticoids was 
found. The secretase inhibitor reversed the glucocorticoid 
resistance; gluco corticoids also antagonised the eﬀ ects of 
Notch inhibition on the intestinal epithelium and thus 
protected against gastro intestinal toxicity.144 These results, 
done both in vitro on T-cell acute lymphoblastic leukaemia 
cells and in vivo in mice, open the door to new therapeutic 
trials of γ-secretase inhibitors in cancer.134,145 A better 
understanding of the mechanisms through which these 
inhibitors cause gastrointestinal toxicity might aid the 
development of other strategies to reverse this toxicity. 
However, treatment with gluco corticoids can have its own 
severe side-eﬀ ects, particularly in the long term, and 
therefore this combination therapy is unlikely to be used 
in the chronic treatment of Alzheimer’s disease. 
γ-secretase modulators
Although γ-secretase inhibitors are directed towards the 
quantitative modulation of Aβ production, a fortuitous 
observation several years ago146 suggested the possibility 
that γ-secretase activity could be modulated to obtain a 
qualitative eﬀ ect on Aβ generation. Substantial progress 
has been made recently, although a real clinical 
breakthrough has not yet been achieved.
So far, two types of compounds have been identiﬁ ed as 
potentially clinically useful γ-secretase modulators: 
non-steroidal anti-inﬂ ammatory drugs (NSAIDs) and 
some kinase inhibitors.147,148 One of the NSAIDs, 
ibuprofen, reduced plaque load and brain inﬂ ammation 
in an Alzheimer’s disease mouse model149 and decreased 
the production of the aggregation-prone Aβ42 in vitro, 
favouring instead the production of the shorter Aβ 
peptide Aβ38.146 No substantial eﬀ ect on Notch cleavage 
was observed. This ﬁ nding in 2001 led to a large amount 
of research into the clinical eﬀ ects of NSAIDs on 
Alzheimer’s disease.150 Several small clinical trials with 
NSAIDs in Alzheimer’s disease resulted in inconsistent 
clinical beneﬁ ts, and tolerability of sustained treatment 
was of concern because of well-known severe 
gastrointestinal side-eﬀ ects owing to inhibition of the 
cyclo-oxygenase (COX1) enzyme.151 Another trial with a 
COX2-selective NSAID, rofecoxib, led to no signiﬁ cant 
clinical improvement.152,153
www.thelancet.com/neurology   Vol 9   February 2010 221
Review
To avoid the gastrointestinal side-eﬀ ects of NSAIDs, a 
derivative molecule without COX-inhibitory activity, 
tarenﬂ urbil (also known as R-ﬂ urbiprofen), was 
developed.154 This drug belongs to a new class of molecules 
termed selective Aβ42-lowering agents (SALA), because 
these compounds modulate γ-secretase activity to reduce 
the production of Aβ42 without aﬀ ecting the production of 
Aβ40 or Notch cleavage.155,156 Results from photocrosslinking 
experi ments have shown that these γ-secretase modulators 
bind in the N-terminal region of the transmembrane 
domain of APP to modulate its cleavage by γ-secretase.150,157 
This ﬁ nding can help explain how APP cleavage is 
speciﬁ cally modulated without interfering with Notch 
cleavage. In mice, tarenﬂ urbil reduced the brain 
concentrations of Aβ42 and prevented learning and 
memory deﬁ cits.158 
In the 24-month randomised, controlled phase 2 trial of 
patients with mild to moderate Alzheimer’s disease, no 
beneﬁ t of treatment was seen on the rate of cognitive 
decline versus placebo.159 However, patients with mild 
Alzheimer’s disease who received tarenﬂ urbil had a 
signiﬁ cantly lower rate of decline in activities of daily 
living and global function than did those who received 
placebo. Unfortunately, however, this compound did not 
show any clinical beneﬁ t in a recent phase 3 clinical 
trial.160 As expected, no severe gastrointestinal side-eﬀ ects 
were observed.159 Penetration of the blood–brain barrier 
seems to be a major problem for this drug36 and paucity of 
data prevents evaluation of whether eﬀ ective lowering or 
modulation of Aβ production was ever attained in the 
trial. Therefore, as for γ-secretase inhibitors, one of the 
major hurdles is the need to design a targeted γ-secretase 
modulator that can reach therapeutic concentrations in 
the brain.
A tarenﬂ urbil analogue, CHF5074, was recently shown 
to reduce amyloid plaque load and attenuate the spatial 
memory deﬁ cit in transgenic mouse models of 
Alzheimer’s disease, indicating that the use of NSAID 
analogues should still be considered as a potential 
therapeutic strategy for Alzheimer’s disease.161,162
γ-secretase heterogeneity
As described above, the γ-secretase enzyme is assembled 
from four components. However, two diﬀ erent genes 
exist for two of these proteins: PSEN1 and PSEN2, and 
Aph1A and Aph1B.20 The complexity is further increased 
by alternative splicing of the diﬀ erent mRNAs encoded 
by these genes. At least four diﬀ erent combinations are 
therefore possible in human beings, and even more if 
the alternatively spliced variants are taken into 
account.163–166 The Aph1A-containing complex is essential 
for Notch processing during embryogenesis.167,168 Aph1B 
is expressed in mouse and human brain, but 
Aph1B-knockout mice mainly develop as normal. By 
contrast, knockout of Aph1B in a mouse model of 
Alzheimer’s disease unexpectedly rescued several 
phenotypes associated with Alzheimer’s disease.74 These 
Aph1B-knockout mice had decreased Aβ production, a 
much-reduced plaque load, and normal memory 
function. These events occurred without signiﬁ cant 
Notch-related side-eﬀ ects, as neither intestinal metaplasia 
nor involution of spleen and thymus were observed, and 
T-lymphocyte ratios and pancreas histopathology were 
normal.
Both Aph1A and Aph1B γ-secretase complexes are 
equally competent in cleaving synthetic APP and Notch 
substrates. Although the Aph1B-containing complexes 
produced more longer Aβ peptides (Aβ42 and longer) in 
cell-free assays, the total ratio of Aβ42:Aβ40 in brain extracts 
from transgenic and wild-type mice was not signiﬁ cantly 
changed.74 The longer Aβ peptides might therefore be 
degraded in the cell before secretion. The total amount of 
Aβ peptides in Aph1B-knockout mouse and human brain 
material from which Aph1B complexes were removed 
was, however, decreased, emphasising the crucial 
contribution of Aph1B to the total γ-secretase activity in 
the brain. 
This γ-secretase heterogeneity provides new possibilities 
for targeted therapies. As Aph1B is strongly expressed in 
the brain, and apparently does not have a substantial role 
in Notch signalling in peripheral tissues, it is theoretically 
attractive to try to speciﬁ cally target the Aph1B complex. If 
such a drug could be developed, this inhibitor could be 
given to patients, or even as a preventive therapy for 
Alzheimer’s disease, without concerns about potential 
Notch-related side-eﬀ ects. Whether PSEN2-containing 
complexes provide similar opportunities for less toxic drug 
development remains to be investigated. PS2-knockout 
animals have similar phenotypes to wild-type animals, 
with only minimum apoptotic changes in the lung.169 
Furthermore, there is evidence that compounds can target 
PSEN1-containing or PSEN2-containing complexes 
speciﬁ cally in vitro.80 However, to date there have been no 
published reports to suggest that selectively blocking 
PSEN2 function in an Alzheimer’s disease mouse model 
improves Alzheimer-related symptoms. 
Regulation of γ-secretase by G-protein-coupled receptors
Research on the physiological control mechanisms of 
γ-secretase activity might yield novel drug targets. 
This type of work is in its early stages, but two in-
dependent reports indicate that γ-secretase subcellular 
localisation and proteolytic activity might be regulated 
by G-protein-coupled receptors, in particular the 
β2-adrenergic receptor170 and G-protein-coupled receptor 3 
(GPR3).171 GPR3 is an orphan receptor, but is expressed 
in the hippocampus and cortex. This receptor seems to 
promote assembly of the γ-secretase complex, resulting 
in increased traﬃ  cking of the γ-secretase components 
and mature γ-secretase complex to the cell surface, which 
eventually leads to an increase in Aβ generation. 
Activation-induced receptor-mediated endocytosis of the 
β2-adrenergic receptor with the γ-secretase complex also 
results in an increase in Aβ production. Therefore, drugs 
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that modulate the activity of these receptors might 
become useful as alternatives to γ-secretase inhibitors 
and modulators. The diﬀ erential eﬀ ect of GPR3 on APP 
versus Notch processing, indicating that Aβ generation 
can be blocked independently of any eﬀ ects on Notch, 
makes GPR3 a particularly attractive target. 
Conclusions and future directions
As the catalytic core of the γ-secretase enzymes, presenilins 
are key players in the production of aggregation-prone Aβ 
peptides. The many mutations in the presenilin and APP 
genes have provided strong evidence for the amyloid 
hypothesis of Alzheimer’s disease pathogenesis. Although 
patients with autosomal dominant early-onset familial 
Alzheimer’s disease account for less than 0∙5% of all 
patients with Alzheimer’s disease, they share a similar 
neuropathological proﬁ le with patients who have late-onset 
sporadic disease. Hence, much has been learned from 
studying the early-onset mutations. Given their wide 
expression and important biological role, one might expect 
presenilins to be involved in a large range of human 
diseases. So far, however, there is little evidence to support 
associations with diseases other than Alzheimer’s disease. 
Despite more than a decade of research into γ-secretase 
inhibitors, no therapeutic drugs have yet reached the clinic. 
A major obstacle is the toxic Notch-related side-eﬀ ects. If 
γ-secretase inhibitors that inhibit the processing of APP 
while sparing Notch can be further developed, this would 
provide a major breakthrough. Recent insights into the 
heterogeneity of the γ-secretase complexes might help the 
rational design of such compounds. However, even if 
eﬀ ective γ-secretase inhibitors or other Notch-sparing 
γ-secretase therapies can be developed, the blood–brain 
barrier still poses a major problem. 
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